Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05361395
Title First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS


No variant requirements are available.